Volume 14 Issue 2, June 2020

Biotech start-up company NovaGo is developing human antibodies that stimulate nerve repair and regeneration following a stroke. The company’s lead candidate anti-Nogo-A antibody (NG004) is ready for phase 1 trials, and it is looking for partners to develop it through the clinic.

Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.

Covering the whole production chain from the supply end to the value end, Nordic Biovian delivers a comprehensive and reliable manufacturing service, enabling the development of medical therapies.

Biotech company Cellatoz Therapeutics is developing innovative cell therapies by applying its proprietary cells, known as A-to-Z cells to multiple therapeutic areas. The company is now looking for partners to develop the therapies further.

inRegen’s personalized progenitor cell therapy injects autologous kidney cells (REACT) into patients’ damaged kidneys, where cells migrate and restore kidney function. The cell-based treatment is showing signs of promise in ongoing phase 2 trials.

Japanese company Synplogen uses technology based on over a decade of academic research to design and manufacture long and complex sequences of synthetic DNA. The company is also engaged in novel drug discovery and R&D of gene and cell therapies.

Novadip is designing new treatment options for critical size defects, complex small size defects and surgically inaccessible tissue with its patented 3D tissue regeneration technology platform to transform the lives of patients with unmet medical needs.

Aruvant is developing ARU-1801, a one-time, potentially curative gene therapy for sickle cell disease and β-thalassemia. In an ongoing clinical phase 1/2 study, ARU-1801, administered with only reduced intensity conditioning, has provided stable reductions in disease burden and opioid dependence.

MiCAN Technologies has developed Mylc cells, human myeloid lineage cells for use in the study of infectious diseases caused by viruses. The company is also developing a human red blood-like cell product, Mpv. It is hoped that, together, these products will accelerate vaccine and drug development globally.

History has shown that collaborative efforts can have a crucial role in combating viral outbreaks such as the current coronavirus pandemic.

GSK forms multidisciplinary teams to accelerate R&D and address major public health challenges

Amicoat’s environmentally friendly antimicrobial coating technology has a broad spectrum of activity with a low risk of provoking antibiotic resistance. The peptide-based technology effectively eliminates biofilms and can be applied to a wide range of medical devices to reduce healthcare-associated infections.

Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

TAXIS Pharmaceuticals is developing first-in-class anti-resistance drugs to help re-engage widely prescribed but resistance-prone generic antibiotics to treat patients with multidrug-resistant infections. The company is actively looking to partner its lead assets with pharma and to in-license novel anti-resistance drug candidates for development.

By acting directly on human cell machinery, Atriva Therapeutics’ lead candidate antiviral ATR-002 combines several advantages over existing therapies and could combat respiratory diseases such as influenza and COVID-19.

After a slow start to the year, dealmaking for the rest of 2020 is likely to be profoundly affected by the COVID‑19 pandemic.

D&D Pharmatech funds the development of innovative therapeutic and diagnostic solutions to address critical unmet medical needs. D&D subsidiary Theraly Fibrosis is developing a novel treatment for chronic pancreatitis and other fibrotic indications, TLY012. Neuraly, another D&D subsidiary, recently launched a phase 2 study in Parkinson disease.

Making the world’s biomedical knowledge computable.

Noveome Biotherapeutics, Inc. is developing a new class of biologic consisting of the secretome from a novel population of cells derived from the amnion. The biological factors secreted by these cells have unique anti-inflammatory and neuroprotective effects. Presently, the company is looking for partners to drive clinical drug development of its lead product, ST266, in ophthalmic indications.

Panorama Medicine has built a combined genomics and advanced computational analysis platform to develop therapies for diseases treatable through transcriptome modulation. The company is looking to partner its therapeutic solutions through licensing options, or to collaborate on custom screening projects.

With its dynamic end-to-end in-house capabilities, Henlius has developed a unique pipeline of cancer and autoimmune drugs, including HLX01, a biosimilar version of MabThera. The company is now exploring the creation of further biosimilars and immuno-oncology combination therapies.